Literature DB >> 20350646

Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.

Sarah J Hemauer1, Svetlana L Patrikeeva, Tatiana N Nanovskaya, Gary D V Hankins, Mahmoud S Ahmed.   

Abstract

OBJECTIVE: Substrates of placental efflux transporters could compete for a single transporter, which could result in an increase in the transfer of each substrate to the fetal circulation. Our aim was to determine the role of placental transporters in the biodisposition of oral hypoglycemic drugs that could be used as monotherapy or in combination therapy for gestational diabetes. STUDY
DESIGN: Inside-out brush border membrane vesicles from term placentas were used to determine the efflux of glyburide, rosiglitazone, and metformin by P-glycoprotein, breast cancer resistance protein, and multidrug resistance protein.
RESULTS: Glyburide was transported by multidrug resistance protein (43 +/- 4%); breast cancer resistance protein (25 +/- 5%); and P-glycoprotein (9 +/- 5%). Rosiglitazone was transported predominantly by P-glycoprotein (71 +/- 26%). Metformin was transported by P-glycoprotein (58 +/- 20%) and breast cancer resistance protein (25 +/- 14%).
CONCLUSION: Multiple placental transporters contribute to efflux of glyburide, rosiglitazone, and metformin. Administration of drug combinations could lead to their competition for efflux transporters. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350646      PMCID: PMC2848180          DOI: 10.1016/j.ajog.2010.01.035

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  36 in total

Review 1.  Placental transporters relevant to drug distribution across the maternal-fetal interface.

Authors:  V Ganapathy; P D Prasad; M E Ganapathy; F H Leibach
Journal:  J Pharmacol Exp Ther       Date:  2000-08       Impact factor: 4.030

Review 2.  The role of drug transporters at the blood-brain barrier.

Authors:  A G de Boer; I C J van der Sandt; P J Gaillard
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

3.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

5.  The multidrug resistance protein family.

Authors:  P Borst; R Evers; M Kool; J Wijnholds
Journal:  Biochim Biophys Acta       Date:  1999-12-06

6.  Expression of members of the multidrug resistance protein family in human term placenta.

Authors:  M V St-Pierre; M A Serrano; R I Macias; U Dubs; M Hoechli; U Lauper; P J Meier; J J Marin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-10       Impact factor: 3.619

Review 7.  A family of drug transporters: the multidrug resistance-associated proteins.

Authors:  P Borst; R Evers; M Kool; J Wijnholds
Journal:  J Natl Cancer Inst       Date:  2000-08-16       Impact factor: 13.506

8.  Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles.

Authors:  Fumihiko Ushigome; Noriko Koyabu; Shoji Satoh; Kiyomi Tsukimori; Hitoo Nakano; Takanori Nakamura; Takeshi Uchiumi; Michihiko Kuwano; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

9.  Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1.

Authors:  B Benyahia; S Huguet; X Declèves; K Mokhtari; E Crinière; J F Bernaudin; J M Scherrmann; J Y Delattre
Journal:  J Neurooncol       Date:  2004-01       Impact factor: 4.130

10.  Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

Authors:  George E Dailey; Mustafa A Noor; Jong-Soon Park; Simon Bruce; Fred T Fiedorek
Journal:  Am J Med       Date:  2004-02-15       Impact factor: 4.965

View more
  33 in total

Review 1.  Metformin pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Srijib Goswami; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-11       Impact factor: 2.089

2.  Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.

Authors:  John T Szilagyi; Ludwik Gorczyca; Anita Brinker; Brian Buckley; Jeffrey D Laskin; Lauren M Aleksunes
Journal:  Toxicol Sci       Date:  2019-04-01       Impact factor: 4.849

Review 3.  Nuclear receptors as therapeutic targets for Alzheimer's disease.

Authors:  Shweta Mandrekar-Colucci; Gary E Landreth
Journal:  Expert Opin Ther Targets       Date:  2011-07-01       Impact factor: 6.902

4.  Identification of CYP3A7 for glyburide metabolism in human fetal livers.

Authors:  Diana L Shuster; Linda J Risler; Bhagwat Prasad; Justina C Calamia; Jenna L Voellinger; Edward J Kelly; Jashvant D Unadkat; Mary F Hebert; Danny D Shen; Kenneth E Thummel; Qingcheng Mao
Journal:  Biochem Pharmacol       Date:  2014-10-22       Impact factor: 5.858

5.  Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion.

Authors:  Sarah J Hemauer; Svetlana L Patrikeeva; Xiaoming Wang; Doaa R Abdelrahman; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 6.  Oral Agents for the Treatment of Gestational Diabetes.

Authors:  Matthew M Finneran; Mark B Landon
Journal:  Curr Diab Rep       Date:  2018-09-28       Impact factor: 4.810

Review 7.  Using oral agents to manage gestational diabetes: what have we learned?

Authors:  Elizabeth Buschur; Florence Brown; Jennifer Wyckoff
Journal:  Curr Diab Rep       Date:  2015-02       Impact factor: 4.810

8.  Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.

Authors:  Dmitri Madera; Lynn Vitale-Cross; Daniel Martin; Abraham Schneider; Alfredo A Molinolo; Nitin Gangane; Thomas E Carey; Jonathan B McHugh; Christine M Komarck; Heather M Walline; William N William; Raja R Seethala; Robert L Ferris; J Silvio Gutkind
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-13

Review 9.  Placental ABC Transporters: Biological Impact and Pharmaceutical Significance.

Authors:  Anand A Joshi; Soniya S Vaidya; Marie V St-Pierre; Andrei M Mikheev; Kelly E Desino; Abner N Nyandege; Kenneth L Audus; Jashvant D Unadkat; Phillip M Gerk
Journal:  Pharm Res       Date:  2016-09-19       Impact factor: 4.200

10.  Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.

Authors:  Chaojun Xue; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Xiaodong Ma; Zhihao Liu; Xiaochi Ma; Jinyong Peng; Kexin Liu
Journal:  Tumour Biol       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.